NEJM reports phase 3 KEYNOTE-905 results where enfortumab vedotin plus pembrolizumab with surgery improved event-free and overall survival versus surgery alone in cisplatin-ineligible muscle-invasive bladder cancer.
Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905 trial)
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%)
and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years.
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905 trial)
enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%)
enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival
Real-world signal that aligns with EV‑303 / EV‑304
adding EVP prior to surgery does not increase operative complexity.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare